Lid and Lash

Latest News

Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point - Image credit: ©patpitchaya—stock.adobe.com
Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point

July 23rd 2025

The solution missed the primary end point of the trial, which was complete resolution of debris after 6 weeks of twice-daily dosing.

CRU 2025 graphic
CRU 2025: The ABCs of DED and OSD

April 10th 2025

Man smoking a joint Image credit: AdobeStock/lesterman
Cannabis users have increased risk for thyroid eye disease outcomes, study reports

March 24th 2025

Closeup of eye Image credit: AdobeStock/VictoriaKey
Eye-opening effects caused by modified transconjunctival lower blepharoplasty

March 12th 2025

patient with lower lid laxity receives treatment with OptiLIFT administered by optometrist - Image credit: Lumenis
Lumenis unveils OptiLIFT for lower lid laxity and impaired blinking

February 7th 2025

Video Interviews
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.